Answers are grounded in this paper and cite their sources.
Our findings confirmed the unfavorable lipid changes in transmen after the start of GAHT even during a longer follow-up, empathizing the potential clinical impact of these modifications on individual long-term CVD risk. Cocchetti C, Castellini G, Iacuaniello D, et al. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). J Sex Med 2021;18:821-829.
No takes yet. Share an insight, caveat, or question.
Cocchetti et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: